Serotonin

The question every serious franchise investor asks when evaluating the anti-aging and longevity space is the same: is this a trend or a transformation? Serotonin Centers was built on the conviction that the answer is unambiguously the latter. Founded in 2021 by Eric Casaburi — the serial entrepreneur who previously built Retro Fitness into a nationally recognized gym franchise — Serotonin Centers launched from Windermere, Florida, operating under the trade name "Serotonin" and positioning itself explicitly as the nation's first human longevity franchise. Casaburi identified a structural gap in the wellness market: consumers increasingly demanding medically supervised, personalized health optimization under one roof, but finding only fragmented point solutions — a med spa here, a hormone clinic there, a weight loss center somewhere else. Serotonin's model consolidates all of those into a single integrated center offering hormone replacement therapy, medical weight loss, IV therapy, red light therapy, hyperbaric oxygen therapy, body contouring with Emsculpt Neo, aesthetic treatments including Botox and Hydrafacial, CoolSculpting, sexual wellness programs, and a proprietary line of nutraceuticals, skincare products, and wellness apparel. As of the 2025 Franchise Disclosure Document, the brand operates 6 franchised locations across the United States with zero company-owned units, a lean structure that places all operational risk and reward directly with franchisees. The brand has reported 100 franchises either open or under development as of March 2024, signaling that the unit count disclosed in the FDD reflects open locations, while signed agreements and development pipelines are considerably larger. The total addressable market for the global fitness and recreational sports centers category — the segment within which Serotonin is classified — was valued at approximately $123.77 billion in 2024, with the anti-aging and MedSpa subset expanding at an accelerating pace. For franchise investors evaluating whether this Serotonin franchise opportunity belongs in their portfolio, this analysis provides independent, data-driven examination of the cost structure, operating model, revenue picture, and competitive dynamics — not promotional copy.

The industry landscape surrounding the Serotonin franchise investment is defined by powerful, durable secular tailwinds that distinguish this category from cyclical franchise sectors. The global fitness and recreational sports centers market was valued at approximately $148 billion in 2025 and is projected by various analyst groups to reach between $235 billion and $367 billion by the early 2030s, with compound annual growth rates estimated between 4.06% and 8.15% depending on methodology and forecast horizon. North America dominates with a 38.44% global market share as of 2025, and the United States alone accounts for 94.3% of the North American portion, making the domestic franchise opportunity particularly compelling. Consumer behavior is shifting in four measurable ways that directly benefit the Serotonin model. First, the adult segment — Serotonin's core demographic — led the fitness and wellness market with approximately 46.3% share in 2025, and that segment increasingly demands preventative, personalized care rather than reactive medical treatment. Second, personal training and individualized prescriptive health plans are growing at rates that outpace basic gym memberships, with premium hourly sessions priced at $50 to $150 commanding consumer willingness-to-pay that generic wellness formats cannot access. Third, integrated medical wellness — combining clinical oversight with concierge-style service delivery — is emerging as the fastest-growing subsegment within the broader wellness economy, precisely the territory Serotonin occupies. Fourth, the longevity-focused franchise space is expanding at a pace that is drawing capital from entrepreneurs, institutional investors, and multi-unit franchise operators who see healthspan optimization as the defining health investment category of the 2020s. The competitive landscape in this space remains meaningfully fragmented at the local and regional level, as most med spas and anti-aging clinics are independent owner-operated practices rather than scaled franchise systems, creating a structural consolidation opportunity for brands that can systematize clinical delivery and replicate it across markets. Serotonin's timing — entering this fragmented market as the self-described first human longevity franchise — carries both first-mover advantage and first-mover execution risk.

The Serotonin franchise cost structure places this opportunity firmly in the premium-tier of wellness franchise investments, requiring both substantial capital and meaningful financial reserves to execute successfully. The initial franchise fee is $59,000, with total initial investment ranging from approximately $665,634 to $1,363,229 per the most consistent figures in the Franchise Disclosure Document, though one source within the FDD cites an extended range reaching $1,788,879 at the upper end — a spread that reflects the enormous variability in leasehold improvement costs depending on location and buildout condition. The database investment range of $1.13 million to $1.53 million represents a realistic mid-to-upper scenario for a standard market entry. Leasehold improvements alone range from $150,000 to $550,000, the single largest cost driver and the primary reason why two investors in different markets can face dramatically different total capital requirements. Services equipment — the clinical and aesthetic machinery central to the Serotonin service offering — adds $195,400 to $305,400, reflecting the sophisticated nature of the equipment required to deliver treatments like Emsculpt Neo, hyperbaric oxygen therapy, and red light therapy at a clinically credible standard. Startup supplies carry an estimated cost of $63,694 to $71,694, furniture and fixtures add $50,000 to $61,000, and signage contributes $25,000 to $38,000. Additional pre-opening costs include three months of rent at $15,000 to $48,000, professional fees of $8,000 to $25,000, business licenses and permits at $5,000 to $11,000, and a grand opening marketing allocation of $10,000. The ongoing fee structure includes a royalty of 6% of gross monthly revenue and an advertising or national brand fund contribution of $7,500 per month plus 2% of gross revenue — a combined ongoing cost structure that investors should model carefully against projected revenue when stress-testing unit economics. The minimum liquid capital requirement is $500,000 and minimum net worth is $2,000,000, classifying this as an investment accessible only to well-capitalized individuals or investment groups. At fees directly paid to the franchisor of at least $79,390 in aggregate, this is not a low-cost entry point, and investors should account for working capital needs beyond the published investment range to sustain operations through the ramp period.

The Serotonin franchise operating model is built around a medically supervised wellness center that requires both licensed clinical professionals and certified health coaches working in coordination to deliver personalized prescriptive plans across four service pillars: hormone optimization, aesthetic enhancement, weight control, and immunity support. Each center is designed as an integrated ecosystem where a team of health coaches and medical practitioners develop individualized treatment programs for clients, a model that requires more complex staffing than a conventional fitness or personal training franchise. The staffing requirement — which must include credentialed medical practitioners capable of supervising hormone replacement therapy and overseeing injectable aesthetic treatments — elevates labor costs and creates a recruitment challenge that franchisees in smaller metro markets may find more pronounced than those in major urban centers. The initial training program is mandatory for the franchisee or Operating Principal and the designated Manager before the location opens, conducted at Serotonin's headquarters, an approved alternate location, or virtually, offered at least quarterly. One source specifies the initial program duration at two weeks, covering general operations and clinical services delivery. In addition to initial training, the franchisor provides a resource library covering operational best practices and marketing materials, along with site selection assistance and lease negotiation guidance — critical support functions for a brand whose buildout costs are heavily influenced by site selection decisions. The franchise agreement runs for a term of 10 years with a 5-year renewal option, and exclusive territories may be available granting the franchisee protection from competing Serotonin units within a defined geographic area. The model requires active owner-operator involvement, particularly in the early stages of building clinical protocols, recruiting medical staff, and establishing patient acquisition systems, though the presence of a Manager role in the training requirements suggests the brand envisions an eventual owner-operator-with-management-team structure. Multi-unit agreements are actively pursued by the company, evidenced by development deals in Jacksonville (six locations), Boston (six locations), and Charleston (three planned locations), indicating corporate preference for operators with the financial depth and management infrastructure to scale.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document in a way that provides complete unit-level transparency, though some performance representations have been publicly cited in connection with the brand. The figures that have circulated include yearly gross sales of $641,702 and an average revenue per unit figure reported elsewhere as $1,630,133 — a meaningful discrepancy that underscores the importance of independently verifying any performance representations directly against the current FDD before making investment decisions. The owner-operator estimated earnings range cited publicly is $96,256 to $128,341 annually, and the franchise payback period has been estimated at 12.3 to 14.3 years — a relatively long recovery horizon compared to some franchise categories, though consistent with a capital-intensive, service-differentiated medical wellness model. To contextualize these figures: an investment of $1.13 million at the low end of the database range, with estimated owner earnings of $96,256 to $128,341, implies a simple payback in the range of 8.8 to 11.7 years before accounting for royalties, advertising fees, and ongoing operational costs — tighter than the 12 to 14-year estimate once those ongoing obligations are factored into net profitability. The royalty and ad fund structure — 6% plus $7,500 per month plus 2% — represents meaningful monthly obligations that require consistent revenue generation to sustain. Prospective franchisees should note that revenue alone does not indicate profitability; operating a clinical wellness center with licensed medical practitioners, specialized equipment maintenance contracts, and premium supplies creates a cost structure that bears little resemblance to a service franchise with lower variable costs. The FPI Score of 62 out of 100, categorized as Moderate by the PeerSense franchise performance index, reflects the brand's early-stage development, expansion momentum, and inherent uncertainty associated with a concept that has operated as a franchise system since 2021 — a score that warrants careful due diligence rather than dismissal or uncritical enthusiasm.

Serotonin's unit count growth from zero franchised locations in 2021 to 6 open units as of the current FDD, alongside a reported pipeline of 100 open and under development as of March 2024, reveals a brand in active scaling mode rather than steady-state maturity. Q1 2025 brought five new openings across Charleston, SC; Stamford, CT; Ortega, FL; Mansfield, TX; and Cherry Hill, NJ — representing greater than 50% growth in open locations compared to Q4 2024, an exceptional acceleration rate for a young franchise system. Multi-unit development agreements in Jacksonville (September 2023, six locations), Boston (Fall 2024, six locations operated by Steve and Casey Barker), and Chicago's DuPage County (first location targeted within 2024) demonstrate that multi-unit operators with substantial financial resources are committing to the brand at scale. The first South Carolina location opened in Charleston in September 2025 as the first of three planned for the greater Charleston market, and upcoming development activity spans New Jersey, Florida, Virginia, Missouri, and North Carolina. The competitive moat Serotonin is attempting to construct rests on four pillars: the first-mover position as the branded national human longevity franchise, a proprietary product ecosystem that includes Serotonin-branded nutraceuticals, skincare products, and wellness apparel that create recurring revenue streams beyond service delivery, clinical partnerships with major aesthetic brands including Allergan, and a service breadth — spanning hormone therapy, body contouring, IV therapy, hyperbaric oxygen, and medical aesthetics — that is difficult for single-service competitors to replicate. Eric Casaburi's prior experience scaling Retro Fitness provides the brand with credible franchise infrastructure expertise, though investors should note that franchising a medically supervised clinical model is operationally more complex than franchising a traditional fitness center. Employee reviews on public platforms from General Manager-level staff in Nashville and Newton have identified training inconsistencies and support gaps, which the corporate team will need to systematically address as the brand scales from a handful of locations to the hundred-unit pipeline it has publicly committed to building.

The ideal Serotonin franchisee is a well-capitalized individual or investment group with a minimum of $500,000 in liquid capital and $2,000,000 in net worth, and either a background in healthcare, clinical services, or multi-unit franchise operations. Given the staffing complexity of running a medically supervised wellness center, candidates with prior experience managing licensed professionals — whether in healthcare, aesthetics, or a closely adjacent service category — will navigate the operational learning curve more efficiently than those whose backgrounds are limited to traditional retail or service franchises. Single-unit operators are accepted but the brand's development strategy is clearly oriented toward multi-unit agreements, as evidenced by the six-unit deals in Jacksonville and Boston and the three-unit plan for Charleston — suggesting that candidates willing to commit to development agreements covering multiple locations will receive prioritized territory access and franchisor attention. Geographic opportunity currently spans emerging markets including New Jersey, Virginia, Missouri, Massachusetts, North Carolina, and Texas, with the South holding the highest current concentration at four existing locations. The franchise agreement term is 10 years with a 5-year renewal option, providing a 15-year maximum runway under a single agreement — adequate for an investor entering a capital-intensive buildout to recoup investment and build equity, provided unit economics perform at or above the levels cited in publicly available performance data. Transfer and resale considerations are particularly important in a medically supervised franchise where clinical licensing and practitioner relationships are embedded in the business value, and prospective investors should thoroughly review transfer provisions in the FDD with qualified legal counsel before signing.

The Serotonin franchise investment thesis rests on a genuine structural opportunity: the convergence of a $148 billion global fitness and wellness market growing at between 4% and 8% annually, a fragmented competitive landscape dominated by independent operators rather than scaled franchise systems, and rising consumer demand for personalized, medically supervised longevity services that a solo practitioner cannot cost-effectively deliver at scale. At a total initial investment ranging from approximately $665,634 to potentially $1,363,229 or higher depending on market and buildout, with minimum liquidity of $500,000 and minimum net worth of $2,000,000, this is a premium-tier franchise opportunity that demands rigorous due diligence rather than a quick decision. The FPI Score of 62 — Moderate — reflects real uncertainty in an early-stage system alongside real momentum in a validated market category. Employees have flagged training and support gaps that the brand, having grown rapidly since its 2021 founding, must address to sustain franchisee performance and satisfaction as scale increases. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools to help investors evaluate the Serotonin franchise cost and opportunity against competing wellness and longevity franchise concepts with full analytical rigor. Explore the complete Serotonin franchise profile on PeerSense to access the full suite of independent franchise intelligence data.